Martin’s biotech fund to inject €39m into US drug company
Malin, the Irish biotech investment fund backed by former Elan boss Kelly Martin, will pump €39 million into an American drug company.
Malin, which intends to list on the Irish stock exchange later this month, has agreed to pay $18 million (€16.5 million) for an initial 41 per cent in Serenus Biotherapeutics. Depending on how Serenus performs, Malin will raise its shareholding in the company to 76 per cent for an additional $25 million.
Martin will become chairman of Serenus as part of the investment. Serenus is developing treatment for chronic and infectious diseases and plans to concentrate on the African market.
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply